Last $14.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
GEDSF On Other Exchanges
As of 8:10 PM 02/25/15 All times are local (Market data is delayed by at least 15 minutes).

richter gedeon -spons gdr (GEDSF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $16.00
52 Week Low
02/25/15 - $14.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

richter gedeon -spons gdr (GEDSF) Related Businessweek News

No Related Businessweek News Found

richter gedeon -spons gdr (GEDSF) Details

Chemical Works of Gedeon Richter Plc. engages in the research, development, manufacture, and marketing of pharmaceutical products in Hungary and internationally. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. Its gynecological products include contraceptives, emergency contraceptives, hormone replacements, fungicides, and preparations used for treating uterine fibroids; and central nervous system products comprise products for the treatment of chronic cerebral circulatory disorders, anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as a product for treating neuropathic pain. The company’s cardiovascular products consist of ACE-inhibitor products to lower blood pressure and products for reducing cholesterol. It also produces various over-the-counter pharmaceutical products for various health problems, including Escapelle (Postinor), an emergency contraceptive pill; Panangin for supporting cardiovascular health; Stopdiar to treat diarrhea; Lordestin and Zilola for allergy; and Curiosin for wound care. In addition, the company offers contract development and manufacturing services for the pharmaceutical and biotechnological industries. Chemical Works of Gedeon Richter Plc. was founded in 1901 and is based in Budapest, Hungary.

11,603 Employees
Last Reported Date: 02/9/15
Founded in 1901

richter gedeon -spons gdr (GEDSF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

richter gedeon -spons gdr (GEDSF) Key Developments

Chemical Works of Gedeon Richter plc announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Chemical Works of Gedeon Richter plc announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of HUF 90,079 million compared to HUF 90,928 million a year ago. Profit from operations 12,583 million compared to HUF 3,842 million a year ago. Loss before income tax was HUF 2,346 million compared to profit before income tax of HUF 567 million a year ago. Loss for the period was HUF 4,111 million compared to profit for the period of HUF 2,744 million a year ago. Loss attributable to owners of the parent was HUF 4,186 million compared to profit of HUF 2,901 million a year ago. Diluted loss per share was HUF 23 compared to earnings per share of HUF 15 a year ago. For the year, Total revenues were HUF 353,709 million compared to HUF 351,886 million a year ago. Profit from operations was HUF 39,174 million compared to HUF 46,446 million a year ago. Profit before income tax was HUF 27,803 million compared to HUF 43,636 million a year ago. Profit for the period was HUF 24,705 million compared to HUF 42,431 million a year ago. Profit attributable to owners of the parent was HUF 24,636 million compared to HUF 42,766 million a year ago. Diluted earnings per share were HUF 132 compared to HUF 229 a year ago. Net cash flow from operating activities was HUF 60,724 million compared to HUF 73,942 million a year ago. Payments for property, plant and equipment was HUF 28,399 million compared to HUF 25,302 million a year ago. Payments for intangible assets were HUF 14,771 million compared to HUF 8,304 million a year ago. EBITDA was HUF 68,965 million compared to HUF 75,720 million a year ago. Capital expenditure for the Group including payments for intangible assets totaled HUF 43,170 million compared to HUF 33,606 million reported for 2013. Capital expenditure linked to the development of biotechnology R&D facilities and manufacturing capacity in Hungary was HUF 1,193 million in 2014.

Bayer and Gedeon Richter Announce Major Co-Operation Deal on Distribution of Contraceptive Patch in Europe

Gedeon Richter has entered into a licensing and distribution agreement with Bayer for the latter's low-dose gestodene and ethinyl-estradiol containing transdermal contraceptive patch, to be marketed in the European Union, other European countries, and certain Latin American countries under the brand name Lisvy. Richter is due to make an upfront payment to Bayer on signing the contract, as well as additional milestone payments, dependent on the product's progress in commercialisation. Further sales royalties will be payable to Bayer after launch.

Gedeon Richter Enters into Licence and Distribution Agreement with Bayer HealthCare

Gedeon Richter announced that it entered into a licence and distribution agreement with Bayer HealthCare to commercialize a transdermal contraceptive patch of Bayer in the European Union, in other European countries and in some countries in Latin America. Under the terms of the agreement, Richter will make an upfront payment when the contract is signed and further milestone payments linked to the progress of the commercialization. Royalties will become payable to Bayer after the product launch.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEDSF:US $14.95 USD 0.00

GEDSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 746.00 GBp +6.00
Impax Laboratories Inc $40.05 USD -0.35
Krka dd Novo mesto €59.85 EUR -0.65
Pharmstandard OJSC 1,145 RUB +30.00
Ranbaxy Laboratories Ltd 805.50 INR +22.95
View Industry Companies

Industry Analysis


Industry Average

Valuation GEDSF Industry Range
Price/Earnings 26.8x
Price/Sales 1.8x
Price/Book 1.2x
Price/Cash Flow 26.8x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RICHTER GEDEON -SPONS GDR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at